BOSTON THERAPEUTICS, INC. (OTCMKTS:BTHE) Files An 8-K Changes in Registrant’s Certifying Accountant


BOSTON THERAPEUTICS, INC. (OTCMKTS:BTHE) Files An 8-K Changes in Registrant’s Certifying Accountant
Item 4.01 Change in Registrants Certifying Accountant

On December 2, 2019 (the “Resignation Date”), Liggett & Webb P.A. (the “Former Auditor”) advised Boston Therapeutics, Inc. (the “Company”) that it resigned as the Company’s independent registered public accounting firm.

During the years ended December 31, 2018 and 2017 and through the Resignation Date, the Company has not had any disagreements with the Former Auditor on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the Former Auditor’s satisfaction, would have caused them to make reference thereto in their reports on the Company’s financial statements for such years.

The report of the Former Auditor on the Company’s financial statements for the years ended December 31, 2018 and 2017 did not contain any adverse opinion or disclaimer of opinion, and such report was not qualified or modified as to uncertainty, audit scope, or accounting principle, except that the report contained a paragraph stating there was substantial doubt about the Company’s ability to continue as a going concern.

The Company has requested that our Former Auditor furnish us with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the above statements. A copy of this letter is attached hereto to this Form 8-K as Exhibit 16.1.

Item 9.01 Financial Statements and Exhibits

Boston Therapeutics, Inc. Exhibit
EX-16.1 2 f8k120219ex16-1_bostontherap.htm LETTER FROM LIGGETT & WEBB P.A. Exhibit 16.1   December 5,…
To view the full exhibit click here


Boston Therapeutics, Inc. (BTI) is a pre-clinical and clinical-stage pharmaceutical company. The Company is focused on the development, manufacture and commercialization of carbohydrate-based therapeutic drugs and dietary supplements designed to address blood sugar management and inflammatory diseases. BTI-320 is its lead product candidate. BTI-320 is a Carbohydrate hydrolyzing Enzyme Inhibitor for treatment of patients with Type 2 diabetes. BTI-320 is a non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications, which is designed to reduce post-meal glucose elevation. BTI-320 is in Phase II clinical development. IPOXYN and OXYFEX are in pre-clinical stage of drug development. IPOXYN is indicated for lower limb vascular complications of diabetes. OXYFEX is indicated for veterinary ischemic tissue. It produces and sells SUGARDOWN, a non-systemic carbohydrate-based dietary food supplement to support post-meal blood glucose.